Foghorn Therapeutics Inc.的动态

???????????????? ?????????? #???????????????? ???????? ???????? ???????????????? ?????? ????????????! The idea of pulling many samples to increase the detection power is appealing, but ???? ???????????????????? ??????????' ???????????? ?????? ?????????? ???? ?????????????????? ????????????????????????????????????!?? It often happens that all the cells of interest come from just a handful of samples (and at times even just one single sample), therefore capturing an effect in a single individual. So when you are interpreting the results of a single-cell RNA-Seq experiment, make sure you understand very well sample composition in your cells, and you exclude any confounding effects from mere under-/over-representation. ???? ???????????????????? ???? ?????????? ?????? ?????????????????? ???????? ?????????????????? ?????? ???????????????? ???????? ??????????????????????. ???? ???? ???? ?????? ???????? ????????!?OmicsChart #cancerresearch #singlecell #rnaseq #biomarkers #oncology #bioinformatics #omicschart

Join us at the #FierceBiotechSummit for this featured session on September 30-Oct 1, 2024 ?REGISTER NOW! Save up to $300 with the Advanced Rate: https://ow.ly/lXMK50SWXUY ??What to Expect: CAR-Ts were once hailed as the future of cancer care, but by mid-2023, biotechs began shifting focus to autoimmune conditions, particularly lupus. What’s driving this change? This panel will explore strategies for biotechs navigating this new direction, whether they continue in cancer or move into autoimmune diseases. A big thank you to our Moderators & Speakers for this Panel: - Ruojing (Angus) Liu from Fierce Pharma - Jennifer Michaelson from Cullinan Therapeutics - Kristin Yarema, Ph.D. from Poseida Therapeutics, Inc. - Michael Lehmicke from Alliance for Regenerative Medicine - David Shook from Nkarta, Inc.. Stay Updated by following Fierce Life Sciences Events #FierceBiotech #Biotech #FiercePharma #Pharma #Innovation

???????????????? ?????????? #???????????????? ???????? ???????? ???????????????? ?????? ????????????! The idea of pulling many samples to increase the detection power is appealing, but ???? ???????????????????? ??????????' ???????????? ?????? ?????????? ???? ?????????????????? ????????????????????????????????????!?? It often happens that all the cells of interest come from just a handful of samples (and at times even just one single sample), therefore capturing an effect in a single individual. So when you are interpreting the results of a scRNASeq experiment, make sure you understand very well sample composition in your cells, and you exclude any confounding effects from mere under-/over-representation. ???? ???????????????????? ???? ?????????? ?????? ?????????????????? ???????? ?????????????????? ?????? ???????????????? ???????? ??????????????????????. ???? ???? ???? ?????? ???????? ????????! Posted by Tanya Aneichyk #cancerresearch #singlecell #rnaseq #biomarkers #oncology #bioinformatics

Great to have Jill Walker supporting the development of key products for ENHANC3D GENOMICS, especially on how we can turn disease insights into drug project decision points and potential biomarkers. The insights gained from the regulatory regions of the non-coding genome can give deeper stratification for drug discovery projects and have already shown to accelerate identification of target genes. If you have a GWAS plus driver cell type, or whole genome sequences from responder and non responder - come and talk to us about what the non-coding genome can offer you! [email protected] #PrecisionMedicine #Genomics #BioTech #Biomarkers #Innovation #LifeSciences

Why do preclinical trials often test on mice? I explain why this careful process is essential for developing new medicines while minimizing risks. #Biotech #Oncology

Platform and basket trials allow researchers to explore multiple treatments or target multiple patient populations simultaneously under a single overarching master protocol. Ingrid L?nnstedt shares benefits and challenges of these methodologies: https://hubs.ly/Q02yWS4X0 #biotech #pharma #adaptivetrials #clinicaltrials #oncology

Why do preclinical trials often test on mice? Watch our CEO Vlad Vitoc, MD, MBA’s latest video as he shares why this careful process is essential for developing new medicines while minimizing risks. #Biotech #Oncology

The leading innovators in bacteriophage therapies are driving phages forward and here’s a sneak peek at the headline sessions you won’t want to miss: ?? Spearheading the Investment Opportunities for Bacteriophage Therapies to Become the Standard of Care in Antibiotic Resistant Infections, with Biomedical Advanced Research and Development Authority (BARDA), PHIOGEN Pharma, and Sozo Ventures ??Leveraging Engineered Bacteriophages to Target Cancer Cells & Induce an Immune Response Against Tumors, with TATUM bioscience ??Executing Definitive Pivotal Trials for Bacteriophages to Prove Clinical Efficacy with Armata Pharmaceuticals, Inc. ?? Curious about what else is on the agenda? Explore the full 2025 speaker line-up and session details here ?? https://ter.li/hgi7p6 #Bacteriophage #Phages #Phage #Bacteriophages #AMR?

10 groundbreaking Cambridge spinouts making waves in cancer treatment. ?? ? From cutting-edge diagnostics and innovative therapeutics to advanced research tools, these trailblazing University of Cambridge spinouts are changing the story of cancer. ? We are immensely proud to have supported these ventures from their inception to successful spinouts, and we eagerly anticipate their continued success as they revolutionise cancer prevention, detection, and treatment. ? ?? Learn more in the article below.

Catch the replay of our second webinar in the series: ?? “Non-clinical case study on our patient-derived xenograft animal model with guest speaker from biotech”. ??Click here to access: https://lnkd.in/ePA-bCBE In this session, discover how this innovative approach: ?? Served for triple-negative breast cancer providing crucial non-clinical efficacy data ?? Anticipates clinical trial outcomes and de-risks efficacy and safety assessments ?? Unveils valuable insights into drug mechanisms of action Connect with our speakers: ?? Valerie Castellani Lincontang, PhD, Founder & CSO of Oncofactory and Karine Aguera, CDO at StromaCare, previously R&D Project Leader at ERYTECH Pharma. Explore how our model can be provide you with data efficiently for robust preclinical packages. Learn from our collaboration with Erythech, leveraging this model to advance therapies for rare cancers and orphan diseases. Missed our first webinar too? You can still catch up: https://lnkd.in/exnucnPr #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel #PDX #translational #nonclinical #breastcancer